Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies

Aims GLP‐1 analogs have recently risen to the forefront as effective medications for lowering weight through actions in the central nervous system (CNS). However, their actions in the CNS have not yet been studied in the human brain after longer‐term administration at the highest dose approved for o...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-11, Vol.21 (11), p.2459-2464
Main Authors: Farr, Olivia M., Upadhyay, Jagriti, Rutagengwa, Chelsea, DiPrisco, Bridget, Ranta, Zachary, Adra, Amal, Bapatla, Neha, Douglas, Vivian P., Douglas, Konstantinos A. A., Nolen‐Doerr, Eric, Mathew, Hannah, Mantzoros, Christos S.
Format: Article
Language:English
Subjects:
Antidiabetics
Body weight loss
Brain mapping
Central nervous system
Cholesterol
Cognition
Food
Functional magnetic resonance imaging
GLP‐1
liraglutide
Medical imaging
MRI
Neuroimaging
Obesity
Reinforcement
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims GLP‐1 analogs have recently risen to the forefront as effective medications for lowering weight through actions in the central nervous system (CNS). However, their actions in the CNS have not yet been studied in the human brain after longer‐term administration at the highest dose approved for obesity (liraglutide 3.0 mg). Materials and Methods A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo‐controlled, double‐blind, cross‐over trial after 5 weeks of dose escalation. Neurocognitive and neuroimaging (fMRI) responses to food cues were examined at the clinical research center of Beth Israel Deaconess Medical Center. Results While using liraglutide, patients lost more weight (placebo‐subtracted −2.7%; P 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13827